AU2013239070A1 - Cellular markers for diagnosis of Alzheimer's disease and for Alzheimer's disease progression - Google Patents
Cellular markers for diagnosis of Alzheimer's disease and for Alzheimer's disease progression Download PDFInfo
- Publication number
- AU2013239070A1 AU2013239070A1 AU2013239070A AU2013239070A AU2013239070A1 AU 2013239070 A1 AU2013239070 A1 AU 2013239070A1 AU 2013239070 A AU2013239070 A AU 2013239070A AU 2013239070 A AU2013239070 A AU 2013239070A AU 2013239070 A1 AU2013239070 A1 AU 2013239070A1
- Authority
- AU
- Australia
- Prior art keywords
- lin
- cells
- cd11b
- level
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 105
- 230000005750 disease progression Effects 0.000 title abstract description 9
- 230000001413 cellular effect Effects 0.000 title abstract description 7
- 238000003745 diagnosis Methods 0.000 title description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 83
- 239000008280 blood Substances 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 71
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 494
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 494
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 443
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 443
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 401
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 401
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 369
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 369
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 331
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 331
- 210000004027 cell Anatomy 0.000 claims description 221
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 160
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 160
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 97
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 47
- 230000000770 proinflammatory effect Effects 0.000 claims description 42
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 40
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 40
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 39
- 210000002074 inflammatory monocyte Anatomy 0.000 claims description 38
- 210000005259 peripheral blood Anatomy 0.000 claims description 17
- 239000011886 peripheral blood Substances 0.000 claims description 17
- 230000007423 decrease Effects 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 12
- 230000002596 correlated effect Effects 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 238000013399 early diagnosis Methods 0.000 abstract description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 45
- 108010058597 HLA-DR Antigens Proteins 0.000 description 45
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 33
- 210000001616 monocyte Anatomy 0.000 description 25
- 210000003169 central nervous system Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 230000004770 neurodegeneration Effects 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000005784 autoimmunity Effects 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- 108010004469 allophycocyanin Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000004766 neurogenesis Effects 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 102000004452 Arginase Human genes 0.000 description 3
- 108700024123 Arginases Proteins 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 229960003776 glatiramer acetate Drugs 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000030968 tissue homeostasis Effects 0.000 description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- -1 CD11c Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100021282 Caenorhabditis elegans lin-9 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000030452 Transient pseudohypoaldosteronism Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000007175 bidirectional communication Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008496 central nervous system homeostasis Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000001073 episodic memory Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615465P | 2012-03-26 | 2012-03-26 | |
| US61/615,465 | 2012-03-26 | ||
| PCT/IL2013/050277 WO2013144957A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013239070A1 true AU2013239070A1 (en) | 2014-11-13 |
Family
ID=49258360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013239070A Abandoned AU2013239070A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of Alzheimer's disease and for Alzheimer's disease progression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150057176A1 (enExample) |
| EP (1) | EP2831584B1 (enExample) |
| JP (1) | JP6276252B2 (enExample) |
| KR (1) | KR20140145173A (enExample) |
| CN (1) | CN104471394B (enExample) |
| AU (1) | AU2013239070A1 (enExample) |
| CA (1) | CA2907909A1 (enExample) |
| ES (1) | ES2819174T3 (enExample) |
| IL (1) | IL234779A (enExample) |
| WO (1) | WO2013144957A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6312302B2 (ja) * | 2014-01-06 | 2018-04-18 | 公益財団法人ヒューマンサイエンス振興財団 | 脳梗塞の診断マーカー |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| JP6499342B2 (ja) * | 2018-03-19 | 2019-04-10 | 隆樹 日和佐 | 脳梗塞の診断マーカー |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| WO2020198299A1 (en) * | 2019-03-26 | 2020-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for characterizing and treating alzheimer's disease |
| CN111727260A (zh) * | 2019-10-15 | 2020-09-29 | 湖南乾康科技有限公司 | 中间型单核细胞在制备诊断和预测ad药物中的应用 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| CN112562867A (zh) * | 2021-02-22 | 2021-03-26 | 天津迈德新医药科技有限公司 | 一种预测极早期hiv感染风险的装置、存储介质和电子装置 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| KR102745500B1 (ko) * | 2022-09-02 | 2024-12-23 | 한양대학교 에리카산학협력단 | 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법 |
| CN116270741B (zh) * | 2023-02-28 | 2025-10-24 | 东莞市东南部中心医院 | 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用 |
| CN117122612B (zh) * | 2023-07-07 | 2024-08-27 | 河络新图生物科技(上海)有限公司 | 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1248643E (pt) * | 2000-01-20 | 2005-10-31 | Yeda Res & Dev | Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora |
| US20020137108A1 (en) * | 2000-11-08 | 2002-09-26 | Michael Mullan | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease |
| KR20040081431A (ko) * | 2001-12-06 | 2004-09-21 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 운동신경 질환의 치료용 백신 및 치료 방법 |
| ES2350895T3 (es) * | 2004-08-19 | 2011-01-28 | University College Cardiff Consultants Limited | Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia. |
| MX349711B (es) * | 2008-09-18 | 2017-08-09 | Cedars Sinai Medical Center | Método óptico para la detección de la enfermedad de alzheimer. |
| CA2792471A1 (en) | 2010-03-10 | 2011-09-15 | Yeda Research And Development Co. Ltd | Cellular blood markers for early diagnosis of als and for als progression |
-
2013
- 2013-03-21 US US14/388,369 patent/US20150057176A1/en not_active Abandoned
- 2013-03-21 EP EP13767635.9A patent/EP2831584B1/en active Active
- 2013-03-21 CN CN201380027520.5A patent/CN104471394B/zh active Active
- 2013-03-21 ES ES13767635T patent/ES2819174T3/es active Active
- 2013-03-21 WO PCT/IL2013/050277 patent/WO2013144957A1/en not_active Ceased
- 2013-03-21 KR KR1020147029916A patent/KR20140145173A/ko not_active Withdrawn
- 2013-03-21 AU AU2013239070A patent/AU2013239070A1/en not_active Abandoned
- 2013-03-21 JP JP2015502555A patent/JP6276252B2/ja active Active
- 2013-03-21 CA CA2907909A patent/CA2907909A1/en not_active Abandoned
-
2014
- 2014-09-22 IL IL234779A patent/IL234779A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140145173A (ko) | 2014-12-22 |
| JP6276252B2 (ja) | 2018-02-07 |
| WO2013144957A1 (en) | 2013-10-03 |
| US20150057176A1 (en) | 2015-02-26 |
| CA2907909A1 (en) | 2013-10-03 |
| CN104471394A (zh) | 2015-03-25 |
| JP2015511721A (ja) | 2015-04-20 |
| EP2831584A4 (en) | 2015-10-07 |
| CN104471394B (zh) | 2017-04-05 |
| EP2831584B1 (en) | 2020-06-17 |
| IL234779A (en) | 2017-12-31 |
| ES2819174T3 (es) | 2021-04-15 |
| EP2831584A1 (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2831584B1 (en) | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression | |
| Milo et al. | Revised diagnostic criteria of multiple sclerosis | |
| Richartz et al. | Decline of immune responsiveness: a pathogenetic factor in Alzheimer’s disease? | |
| Xu et al. | High prevalence of mild cognitive impairment in the elderly: a community-based study in four cities of the Hebei Province, China | |
| Hatemi et al. | One year in review 2017: Behçet’s syndrome | |
| Chen et al. | Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood | |
| US20150209404A1 (en) | Cellular blood markers for early diagnosis of als and for als progression | |
| Wu et al. | A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's disease | |
| EP3467497A1 (en) | Method for analyzing expression of smn protein nuclear body | |
| Qi et al. | Overexpression of programmed cell death-1 and human leucocyte antigen-DR on circulatory regulatory T cells in out-of-hospital cardiac arrest patients in the early period after return of spontaneous circulation | |
| Sebastian et al. | Non-classical monocytes and its potential in diagnosing sepsis post cardiac surgery | |
| Green et al. | Blood biomarkers discriminate cerebral amyloid status and cognitive diagnosis when collected with ACD-A anticoagulant | |
| Frisullo et al. | The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis | |
| EP3128327B1 (en) | Method for detecting smn protein expression | |
| CA2941460C (en) | Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing parkinson's disease | |
| Fischer et al. | VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly | |
| Ma et al. | Terminally differentiated cytotoxic CD4+ T cells were clonally expanded in the brain lesion of radiation‐induced brain injury | |
| Bădulescu et al. | Immune thrombocytopenic purpura: Correlations between thrombocytopenia severity and its clinical symptoms | |
| JP4455753B2 (ja) | 精神分裂病の皮膚テスト | |
| D'Auria | Peripheral blood infl ammatory markers as signals of mental disorders in a sample of elderly people | |
| Jiao et al. | Confocal Corneal Microscopy in the Evaluation of Immune-related Motor Neuron Disease Syndrome | |
| Traboulsee et al. | Epidemiology & Registry | |
| WO2024248642A1 (en) | A method for in vitro diagnosis of multiple sclerosis | |
| Pender et al. | Correlation of Blood T Cell and Antibody | |
| Richartz-Salzburger et al. | Decline of Immune Responsiveness: A Pathogenetic Factor in Alzheimer’s Disease? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |